{"id":"tacrolimus-od-mycophenolic-acid-prednisolone","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Neurotoxicity (tremor, headache)"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Malignancy (increased risk)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tacrolimus inhibits calcineurin and blocks T-cell receptor signaling; mycophenolic acid inhibits inosine monophosphate dehydrogenase to reduce lymphocyte proliferation; prednisolone is a corticosteroid that broadly suppresses immune cell activation and cytokine production. Together, these agents provide complementary immunosuppression to prevent allograft rejection.","oneSentence":"This triple immunosuppressive regimen suppresses T-cell activation and proliferation to prevent organ rejection after transplantation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:10:57.061Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in transplant recipients (kidney, heart, liver, pancreas)"},{"name":"Maintenance immunosuppression post-transplantation"}]},"trialDetails":[{"nctId":"NCT01560572","phase":"PHASE4","title":"Steroid Free Immunosuppression or Calcineurin Inhibitor Minimization After Basiliximab Induction Therapy in Kidney Transplantation: Comparison With a Standard Quadruple Immunosuppressive Regimen","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2011-04","conditions":"Renal Insufficiency, Kidney Transplantation","enrollment":305}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["advagraf, mycophenolic acid"],"phase":"marketed","status":"active","brandName":"tacrolimus OD, mycophenolic acid, prednisolone","genericName":"tacrolimus OD, mycophenolic acid, prednisolone","companyName":"University Medical Center Groningen","companyId":"university-medical-center-groningen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple immunosuppressive regimen suppresses T-cell activation and proliferation to prevent organ rejection after transplantation. Used for Prevention of organ rejection in transplant recipients (kidney, heart, liver, pancreas), Maintenance immunosuppression post-transplantation.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}